- Home
- NMRK vs TARS Comparison
NMRK vs TARS Comparison
Compare NMRK & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMRK
- TARS
- Stock Information
- Founded
- NMRK 1929
- TARS 2016
- Country
- NMRK United States
- TARS United States
- Employees
- NMRK N/A
- TARS N/A
- Industry
- NMRK Real Estate
- TARS Medicinal Chemicals and Botanical Products
- Sector
- NMRK Finance
- TARS Health Care
- Exchange
- NMRK Nasdaq
- TARS Nasdaq
- Market Cap
- NMRK 1.9B
- TARS 1.7B
- IPO Year
- NMRK 2017
- TARS 2020
- Fundamental
- Price
- NMRK $12.25
- TARS $40.20
- Analyst Decision
- NMRK Strong Buy
- TARS Strong Buy
- Analyst Count
- NMRK 4
- TARS 7
- Target Price
- NMRK $15.67
- TARS $67.14
- AVG Volume (30 Days)
- NMRK 1.2M
- TARS 593.2K
- Earning Date
- NMRK 08-01-2025
- TARS 08-07-2025
- Dividend Yield
- NMRK 0.98%
- TARS N/A
- EPS Growth
- NMRK 81.01
- TARS N/A
- EPS
- NMRK 0.38
- TARS N/A
- Revenue
- NMRK $2,857,497,000.00
- TARS $233,674,000.00
- Revenue This Year
- NMRK $13.78
- TARS $122.94
- Revenue Next Year
- NMRK $9.47
- TARS $44.14
- P/E Ratio
- NMRK $32.51
- TARS N/A
- Revenue Growth
- NMRK 14.48
- TARS 449.03
- 52 Week Low
- NMRK $9.65
- TARS $20.08
- 52 Week High
- NMRK $16.10
- TARS $57.28
- Technical
- Relative Strength Index (RSI)
- NMRK 58.77
- TARS 41.69
- Support Level
- NMRK $11.51
- TARS $39.50
- Resistance Level
- NMRK $12.52
- TARS $41.50
- Average True Range (ATR)
- NMRK 0.41
- TARS 1.48
- MACD
- NMRK 0.08
- TARS 0.11
- Stochastic Oscillator
- NMRK 74.33
- TARS 44.35
About NMRK Newmark Group Inc.
Newmark Group Inc is a commercial real estate advisory firm. It offers services, including leasing and corporate advisory services, investment sales, commercial mortgage brokerage, appraisal and valuation, project management, and property, among others. Newmark offers a diverse array of integrated services and products designed to meet the full needs of both real estate investors/owners and occupiers. The company provides real estate strategic consulting and systems integration services to CFI's clients including many Fortune and Forbes companies, owner-occupiers, government agencies, healthcare, and higher education clients.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.